7 July 2015: Sharp Clinical Services, part of UDG Healthcare plc, (LON: UDG), the leading international provider of healthcare services, has expanded its storage and packaging facilities in the UK by an additional 5,000 square feet, creating an additional 10 roles at the site. The new facility based in Crickhowell is now the fourth unit of the existing Waller House building and comprises of 150 additional pallet spaces and two assembly lines. The Company’s investment is in response to new product introductions approved by the regulatory authorities.
Sharp Clinical Services is a leading provider of specialist clinical supply chain services to both large pharmaceutical and small biotech companies in the UK and US, from drug product development, analytical and manufacturing services through to increasingly complex clinical trial supplies packaging, clinical labeling and clinical distribution services. Sharp Clinical Services has a proven track record in managing the entire clinical supply chain and has a Global Depot Network of 18 depots supporting over 25 countries.
Ian Morgan, General Manager of Sharp Clinical Services UK, commented on the expansion: “The expansion of the Crickhowell facility is a landmark moment for Sharp Clinical Services in the UK, and enables us to deliver excellent, high quality service to our existing and new customers as demand for our services increases in the UK. The first commercial test ran at the end of May and full production will begin in July.”
Frank Lis, President of Sharp Clinical Services added: “This expansion has increased our global footprint and will allow us to provide our customers with a full range of services, from formulation development and pre-clinical supplies through to product launch.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ponsegromab Significantly Improves Body Weight in Patients with Cancer Cachexia
September 17th 2024Results of a Phase II study of ponsegromab showed significant improvements in body weight, muscle function, and overall symptoms for patients with cancer cachexia, offering hope for a new targeted treatment.
Imfinzi Plus Imjudo Shows Significant Five-Year Survival Improvement in Unresectable Liver Cancer
September 16th 2024Data from the Phase III HIMALAYA trial found the combination of Imfinzi plus Imjudo reduced the risk of death by 24% compared to sorafenib in patients with unresectable hepatocellular carcinoma.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Ponsegromab Significantly Improves Body Weight in Patients with Cancer Cachexia
September 17th 2024Results of a Phase II study of ponsegromab showed significant improvements in body weight, muscle function, and overall symptoms for patients with cancer cachexia, offering hope for a new targeted treatment.
Imfinzi Plus Imjudo Shows Significant Five-Year Survival Improvement in Unresectable Liver Cancer
September 16th 2024Data from the Phase III HIMALAYA trial found the combination of Imfinzi plus Imjudo reduced the risk of death by 24% compared to sorafenib in patients with unresectable hepatocellular carcinoma.
2 Commerce Drive
Cranbury, NJ 08512